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Background: CD56 expression has been associated with a poor prognosis in lymphoid neoplasms, including T-cell
acute lymphoblastic leukemia (T-ALL). MicroRNAs (miRNAs) play an important role in lymphoid differentiation, and
aberrant miRNA expression has been associated with treatment outcome in lymphoid malignancies. Here, we
evaluated miRNA expression profiles in normal thymocytes, mature T-cells, and T-ALL samples with and without
CD56 expression and correlated microRNA expression with treatment outcome.
Methods: The gene expression profile of 164 miRNAs were compared for T-ALL/CD56+ (n=12) and T-ALL/CD56-
(n=36) patients by Real-Time Quantitative PCR. Based on this analysis, we decided to evaluate miR-221 and miR-374
expression in individual leukemic and normal samples.
Results: miR-221 and miR-374 were expressed at significantly higher levels in T-ALL/CD56+ than in T-ALL/CD56-
cells and in leukemic blasts compared with normal thymocytes and peripheral blood (PB) T-cells. Age at diagnosis
(15 or less vs grater than 15 years; HR: 2.19, 95% CI: 0.98-4.85; P=0.05), miR-221 expression level (median value as cut
off in leukemic samples; HR: 3.17, 95% CI: 1.45-6.92; P=0.004), and the expression of CD56 (CD56- vs CD56+; HR: 2.99,
95% CI: 1.37-6.51; P=0.006) were predictive factors for shorter overall survival; whereas, only CD56 expression
(HR: 2.73, 95% CI: 1.03-7.18; P=0.041) was associated with a shorter disease-free survival rate.
Conclusions: miR-221 is highly expressed in T-ALL and its expression level may be associated with a poorer
prognosis.
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Neural-cell adhesion molecule (N-CAM; CD56) is a
known marker of natural killer (NK) cells [1]. The two
best characterized forms of NK-cell malignancy are the
aggressive NK-cell leukemia (ANKL) and the extra nodal
NK-cell lymphoma, nasal type (ENKL) [2,3]. However,
CD56 is also expressed on a subset of normal T cells
and occasionally on blasts in T-cell acute lymphoblastic
leukemia (T-ALL) [4]. The expression status of CD56* Correspondence: emrego@hcrp.fmrp.usp.br
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distribution, and reproduction in any mediumidentified a subgroup of patients with T-ALL who did
not respond well to therapy [4,5]. From an ontogenetic
point of view, NK cells arise from T/NK bi-potential
common progenitors [6,7]; therefore, NK-cells are func-
tionally and phenotypically very similar to T-cells, par-
ticularly cytotoxic T-cells.
MicroRNAs (miRNAs) play an important role in lym-
phoid differentiation and in innate immune response
[8-10], and aberrant miRNA expression has been asso-
ciated with treatment outcome in hematological malig-
nancies [11-13]. Wang et al. demonstrated that miR-378
and miR-30e are suppressors of NK cell cytotoxicity and
their expression is regulated by IFNα [14]. Furthermore,
Chiaretti et al. recently described a large set of myeloid-d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Gimenes-Teixeira et al. Experimental Hematology & Oncology 2013, 2:10 Page 2 of 8
http://www.ehoonline.org/content/2/1/10related miRNAs overexpressed in a subset of adult T-ALL
patients; interestingly, the “myeloid-like” cases presented
with higher expression levels of miR-223 and poorer prog-
noses compared with T-ALL patients without overexpres-
sion of myeloid-related genes [15].
Some miRNAs may be relevant in T-ALL leukemoge-
nesis. Mavrakis et al. identified five miRNAs (miR-19b,
miR-20a, miR-26a, miR-92, and miR-223) in a human
T-ALL library that were capable of promoting T-ALL
development in a mouse model [16]. Moreover, these
miRNAs acted synergistically with tumor suppressor
genes implicated in the pathogenesis of T-ALL [16]. In
the present study, we compared expression of 164
miRNAs in T-ALL blasts with and without CD56 ex-
pression and correlated these profiles with T-cell devel-
opment and treatment outcome.
Results and discussion
Initially, we identified 56 miRNAs with higher expres-
sion and 35 with lower expression levels in the T-ALL/
CD56+ group compared with the T-ALL/CD56- group
(Additional file 1: Table S1). Expression of miR-221 andFigure 1 Quantitative analysis of miR-221 (A) and miR-374 (B) expres
peripheral blood, and CD3+/CD4+/CD8+ thymocytes. Leukemic samples
of miRNAs was quantified by Real-Time Quantitative PCR (RQ-PCR). The ho
2-ΔCt. T-ALL samples were categorized according to presence of the CD56
negative (T-ALL/CD56-). Asterisks indicate significant differences between gmiR-374 were higher in T-ALL/CD56+ compared with
T-ALL/CD56- cells, with 271- and 181-fold changes, re-
spectively, and were chosen for further analyses. Irre-
spective of CD56 expression, miR-221 (Figure 1A) and
miR-374 (Figure 1B) expression were higher in leuke-
mic blasts compared with normal peripheral blood (PB)
T-cells and thymocytes. By adopting the upper limits of
the 95% confidence intervals of miR-221 and miR-374
expression in the normal T/CD3+ samples as cut-offs,
48/48 (100%) and 38/47 (81%) of the T-ALL samples, re-
spectively, had expression higher than the cut-off values.
We did not detect differences in miR-221 and miR-
374 expression when comparing triple positive thy-
mocytes (CD3+/CD4+/CD8+) and mature T-cells in PB
of healthy subjects. Our results do not corroborate the
study by Kirigin et al. [8], which analyzed miRNAs in
different stages of T-cell differentiation in the murine
thymus and bone marrow using next generation sequen-
cing. The authors demonstrated that there was greater
expression of miR-221 and miR-222 in early stages com-
pared with mature thymocytes. However, the compa-
rison between the two studies must be regarded withsion in samples from T-ALL patients, T-cells from normal
from 48 T-ALL patients were obtained from cell banks. The expression
rizontal bars represent the mean of miRNA expression calculated by
cell marker: 12 samples were positive (T-ALL/CD56+) and 36 were
roups (ANOVA test followed by a Dunn’s post-test).
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plex strategy of cell sorting, and analyzed T-cell subsets
that do not completely overlap with those of our study.
The double positive (DP) thymocytes in their study
had the immunophenotype CD90+CD4+CD8+CD3low
and were compared with CD4 single positive (SP) (CD90+
CD4+CD8-CD24lowCD3high), and CD8SP (CD90+CD42
CD8+CD24lowCD3high) subsets. In addition, the most sig-
nificant difference in miR-221 expression demonstrated
by Kirigin et al. [8] was between double negative four
(DN4, CD90+CD4-CD8-CD3lowCD44-CD25-) thymocytes
and CD4SP and CD8SP mature T-cells [8], and such ana-
lysis was not performed in the present study.
miR-221 is up-regulated in several human malignancies;
whereas, there are few reports associating miR-374 with
tumorigenesis. Nevertheless, the mechanisms leading to
the higher expression of these miRNAs are unknown. Re-
cently, Santhekadur et al. [17] demonstrated that RNA
Induced Silencing Complex (RISC) proteins SND1 and
AEG-1 induce miR-221 expression in a NFκB dependent
way in liver cancer cells. An alternative explanation would
be that extracellular stimuli may interfere with miRNAs
expression. With this regard, Davis et al. [18] demons-





High expression Low expression
Age1, years 22.8 (1 – 66) 17.4 (2 – 44)
Gender (M/F) 24(18/6) 24 (21/3)
Mediastinal mass (%) 14/24(58) 6/24 (25)
Lymphadenopathy (%) 15/24(62.5) 21/24 (87.5)
Splenomegaly (%) 16/24(67) 16/24 (67)
Hepatomegaly (%) 15/24(62.5) 16/24 (67)
CNS involvement (%) 1/24(4) 2/24 (8)
Blasts BM1 (%) 77.3 (20 – 100) 90.5 (28 – 100)
Blasts PB1 (%) 63.4 (0 – 100) 78.5 (10 – 100)
Hemoglobin1 (g/l) 10.4 (3.6 – 15.6) 10.4 (4.6 – 17.1)
WBC1 count × 109/l 104 (4.6 – 314) 202.3 (4.5 – 790)
Platelets1 × 109/l 149.4 (9 – 652) 48.8 (9 – 185)
Pre thymic (%) 7/24(29) 4/24(17)
Thymic (%) 7/24(29) 10/24(42)
Mature T (%) 8/24(33) 8/24(33)
CD34 (%) 16/24(67) 8/24(33)
CD56 (%) 11/24(46) 1/24(4)
TdT (%) 18/24(75) 21/24(87)
CNS: central nervous system; WBC: white blood cell; PB: peripheral blood; BM: bone
deoxynucleotidyl transferase. *Significant P-value.
1 Values represent mean (range).Growth Factor (PDGF) signaling through modulation of
p27Kip1. Remarkably, high levels of PGDF signaling were
described as a decisive factor for proliferation and survival
in cytotoxic T and natural killer cell neoplasms [19].
The transcription factor BCL11B has been identified
as a putative target of miR-221 and it has been previ-
ously demonstrated that BCL11B expression is required
to repress natural killer cell–associated genes and essen-
tial for T lineage commitment [20-22]. Overexpression
of BCL11B was reported in T-ALL [23] and in adult
T-cell leukemia/lymphoma [24] and its silencing in
Molt-4 cells was associated with increased expression of
the antiapoptotic protein Bcl-2 [20]. Previously repor-
ted miR-221 targets include the cell cycle regulators
CDKN1B/p27Kip1 and CDKN1C/p57Kip2 [25-27]. Le Sage
et al. [25] demonstrated that cancer cell lines require high
expression of miR-221/222 to maintain low p27kip1 levels
and continuous proliferation. Therefore, it is conceivable
that miR-221 acts as an oncogene through inhibition of
p27kip1 in T-ALL. Another known target of miR-221 is the
receptor c-KIT. Fellicetti et al. [28] showed an inverse
correlation between miR-221 and miR-222 expression and
c-KIT protein levels during melanoma progression. In
addition, c-KIT is rapidly up-regulated following NOTCHients at diagnosis according to expression of miR-221
miR-374
P-value High expression Low expression P-value
0.22 23.6 (1 – 66) 16.8 (2 – 44) 0.49
0.46 24(21/3) 23(17/6) 0.12
0.15 15/24 (62.5) 5/23(22) 0.13
0.26 16/24 (67) 19/23(83) 0.24
0.66 17/24 (71) 14/23(61) 0.6
0.99 17/24 (71) 13/23(56.5) 0.44
0.56 2/24 (8) 1/23(4) 0.53
0.09 77.6 (20 – 100) 90.7 (28 – 100) 0.64
0.18 61.5 (0 – 100) 86 (10 – 100) 0.45
0.97 10.1 (3.6 – 15.8) 10.8 (5.3 – 17.1) 0.4
0.06 118 (4.5 – 781) 196 (18 – 789) 0.61
0.009* 140 (9 – 652) 55.8 (9 – 231) 0.03*
0.31 6/24 (25) 5/23(22) 0.81
0.54 9/24 (37.5) 7/23(30) 0.51
0.98 7/24 (29) 9/23(39) 0.37
0.042* 13/24 (54) 11/23(48) 0.56
0.001* 12/24 (50) 1/23(4) <0.001*
0.46 17/24 (71) 21/23(91) 0.28
marrow; cCD3: cytoplasmic CD3; sCD3: surface CD3; TdT: terminal
Figure 2 Disease-free survival (2A-2D) and overall survival (2E-2H) in T-ALL patients according to miR-221 and miR-374 expression.
2A-2B and 2E-2F represent analyses in the whole population; whereas, 2C-2D and 2G-2H represent analyses in only T-ALL/CD56- patients.
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primitive cells into non T-cell fates (NK or myeloid) was
found to be c-kit independent [28].
For the analysis of the relevance of miR-221 and miR-
374 expression levels in the response to treatment, we
arbitrarily divided T-ALL patients in low (≤ median
value in all T-ALL samples) or high (> than the median
value) expression groups. The main clinical and labora-
tory features at diagnosis are summarized in Table 1.
The only significant differences between patients with
high versus low expression of miR-221 and miR-374
were higher platelet counts in patients expressing higher
levels of miR-221 (P = 0.009) and miR-374 (P = 0.03)
and a higher frequency of CD34+ cases in the group
with higher miR-221 expression (P = 0.042). The mean
follow-up among survivors was 27 months (range, 12 to
42 months). The complete hematological remission (CR)
rate for the whole population was 66% and did not dif-
fer between high- and low- miR-221 (54% versus 79%;
P = 0.125) and miR-374 (62% versus 69%; P = 0.76) ex-
pression groups. In the whole population, high miR-221
patients had a lower disease-free survival (DFS) (46%)
compared with low miR-221 patients (72%, P = 0.06;
Figure 2A); while, miR-374 did not impact the DFS (69%
versus 52%, P = 0.229; Figure 2B). When the analysis
was restricted to T-ALL/CD56- patients, the DFS did not
differ between low and high miR-221 (76% versus 51%,
P = 0.111; Figure 2C) and miR-374 groups (69% versus
66%, P = 0.749; Figure 2D).
Patients with high miR-221 expression had significantly
lower 5-year OS rates compared with those with low miR-
221 expression (14% versus 57%, P = 0.002; Figure 2E).
Among T-ALL/CD56- patients, those with higher miR-
221 expression had lower OS (17% versus 60%, P = 0.024;Table 2 Univariate and multivariate analyses for CR, OS, and
End point Model variables Univariate anal
HR OR
CR miR-221 expression (low vs high) 0.63
WBC counts (≤ 30×109/L vs > 30×109/L) 1.55
Age at diagnosis (≤ 15 vs > 15) 1.68
CD56 expression (CD56- vs CD56+) 0.33
OS miR-221 expression (low vs high) 3.17
WBC counts (≤ 30x109/L vs > 30×109/L) 0.69
Age at Diagnosis (≤ 15 vs > 15) 2.19
CD56 expression (CD56- vs CD56+) 2.99
DFS miR-221 expression (low vs high) 1.87
WBC counts (≤ 30×109/L vs > 30×109/L) 1.76
Age at diagnosis (≤ 15 vs > 15) 0.77
CD56 expression (CD56- vs CD56+) 2.73
Abbreviations: OS: overall survival; DFS: disease-free survival; CR: complete remissionFigure 2G). No difference in OS was observed based on
miR-374 expression when considering the whole popula-
tion (40% versus 29% in low- versus high-miR374 groups,
P = 0.173; Figure 2F) or just T-ALL/CD56- patients
(40% versus 50% in low- versus high-miR374 groups,
P = 0.947; Figure 2H). In the univariate analysis, ex-
pression of miR-221 (HR: 3.17, 95% CI: 1.45 to 6.92;
P = 0.004), CD56 expression (HR: 2.99, 95% CI: 1.37 to
6.51; P = 0.006), and age (HR: 2.19, 95% CI: 0.98 to 4.85;
P = 0.05) were associated with poorer OS; whereas, only
CD56 expression was predictive of poorer DFS (HR: 2.73,
95% CI: 1.03 to 7.18; P = 0.041). Nonetheless, these factors
were not independent after adjustment (Table 2).
We selected the T-ALL/CD56+ and CD56- subgroups
based on previous studies by Dalmazzo et al. [4] and
Fischer et al. [29], which suggest that CD56 identifies a
subgroup of patients with distinct immunophenotypic
and clinical features, such as higher resistance to therapy
and older age. Nevertheless, after risk adapted treatment,
the prognostic impact of CD56 expression was not sig-
nificant in the study by Fisher et al. [29] in contrast to
the results reported by Dalmazzo et al. [4]. We must
point out that 47/48 (98%) patients reported here were
also included in the study of Dalmazzo et al. [4], al-
though the follow-up data were updated.
Our results suggest that miR-221 may be a useful bio-
marker in T-ALL. Patients with T-ALL/CD56-with high
expression of miR-221, as well as those with T-ALL/
CD56+ presented shorter OS and, therefore may require
a more careful monitoring of the response to treatment
and/or may be considered candidates to more intensive
therapy. However, our conclusions are limited by the
sample size and need to be further investigated in a
larger cohort.DFS in 48 patients with T-ALL
ysis Multivariate analysis
95% CI P-value HR OR 95% CI P-value
0.17 2.39 0.507 1.71 0.26 10.9 0.571
0.32 7.41 0.581 0.92 0.11 7.15 0.94
0.43 6.54 0.454 2.63 0.53 12.9 0.234
0.08 1.38 0.133 0.14 0.01 1.2 0.073
1.45 6.92 0.004 2.31 0.92 5.81 0.074
0.29 1.64 0.412 1.41 0.53 3.7 0.481
0.98 4.85 0.05 2.2 0.96 5 0.059
1.37 6.51 0.006 2.04 0.76 5.46 0.155
0.89 3.92 0.093 1.54 0.57 4.17 0.391
0.81 3.82 0.148 1.81 0.65 5.01 0.25
0.37 1.6 0.488 0.89 0.42 1.9 0.778
1.03 7.18 0.041 2.25 0.69 7.28 0.173
; HR, Hazard ratio; OR: odds ratio; WBC: white blood count.
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Patients
Forty-eight bone marrow samples from T-ALL patients
were analyzed. All cases were diagnosed in the Hematolo-
gy Laboratory of the University Hospital of the Medical
School of Ribeirão Preto, University of São Paulo from
May 1997 to April 2008. The diagnosis of T-ALL was es-
tablished based on the World Health Organization criteria
[30]. Patients were treated according to the HyperCVAD
[31] (n = 6), Berlin-Frankfurt-Munich 90 (BFM-90) [32]
(n = 16), or Brazilian Childhood Leukemia Treatment
Group – Acute Lymphoid Leukemia 99 (GBTLI-ALL99)
[33] (n = 20) protocols. Six patients were excluded from
survival analyses; one patient died before the beginning of
treatment and the others five had no clinical data avai-
lable. This study was approved by the local Ethics Com-
mittee (process #7147/2005).
Purification of thymocytes and peripheral blood T-cells
Thymic samples were obtained as surgical tissue discards
from five pediatric patients (aged 2 days to 5 years) under-
going cardiac surgery at the University Hospital of the
Medical School of Ribeirão Preto. Thymocytes were iso-
lated by cutting the thymic lobes into small pieces and
forcing them through plastic mesh. Triple positive thy-
mocytes (CD3+/CD4+/CD8+) were purified by immuno-
magnetic separation (Miltenyi Biotec) after labeling with
anti-CD4 and anti-CD8 antibodies, and then passed
through a lymphocyte separation column (Miltenyi Biotec,
Germany) for the positive selection of labeled cells. After
isolation, all samples were more than 95% pure.
Peripheral blood mononuclear cells (PBMCs) from
five healthy donors were harvested by centrifugation on
Ficoll-Hypaque (Sigma Aldrich, USA) density gradients,
and PB T/CD3+ cells were isolated using magnetic-
activated cell sorting (MACS; Miltenyi Biotec, Germany),
according to the manufacturer’s protocol. The homogen-
eity of PB T/CD3+ cells was confirmed by flow cytome-
try, and the purity was greater than 85% in all samples.
Immunophenotyping
Immunophenotyping of the blasts was performed by flow
cytometry. The technique and the panel of fluorochrome-
conjugated monoclonal antibodies were described previ-
ously [4]. We also expanded the panel and analyzed the
expression of TdT, CD34, cytoplasmic CD3 (cCD3), sur-
face CD3 (sCD3), CD4, and CD8 in leukemic cells. The
minimum threshold for a positive reaction to a given anti-
body was defined as 20% of blasts positive for the respec-
tive antigen.
RNA extraction and real-time quantitative PCR of miRNAs
Total RNA from leukemic samples and healthy donors
was isolated using Trizol reagent (Invitrogen, Carlsbad,CA, USA). Complementary DNA (cDNA) was synthesized
from 1 μg of total RNA using a High Capacity cDNA re-
verse transcription Kit (Applied BioSystems, Foster City,
CA, USA), following the manufacturer’s instructions.
The TaqManW MicroRNA Assays Human Panel (Applied
BioSystems, Foster City, CA, USA) was employed to as-
sess the expression levels of 164 miRNAs in leukemic
samples. Due to the limited amount of RNA, we pooled
the samples according to the immunophenotype (T-ALL/
CD56+ versus T-ALL/CD56-) and performed a preliminary
analysis comparing the two groups. Comparisons with co-
efficients of variation greater than 5% were excluded. We
defined a strength cut-off for differential expression as ≥ 4
and ≤ 0.25. The fold change was calculated using the com-
parative cycle threshold (Ct) method, in which the geo-
metric mean of expression of RNUs 6B, 19, 38B and 66
was used for normalization.
Based on this preliminary analysis, we decided to eva-
luate expression of miR-221 and miR-374 in individual
T-ALL, normal thymic, and PB samples. TaqMan-based
Real Time Quantitative Polymerase Chain Reaction
(RQ-PCR) assays were performed using specific RT-
stem-looped primers and probes (Applied BioSystems,
Foster City, CA, USA). All reactions were carried out
in duplicate.
Statistical analysis
The median values of miR-221 and miR-374 expression
in leukemic samples were used as references to classify
T-ALL patients into high and low expression groups.
Student’s t and Fisher’s exact tests were employed to
compare differences between the groups. Overall sur-
vival (OS) was estimated by the Kaplan–Meier method.
Differences among groups were compared by log-rank
test. Multivariate regression analysis was performed for
OS using the Cox proportional hazards model. All P-
values were two sided. The level of significance was set
at 5%. All the statistical tests were performed using the
Statistical Package for the Social Sciences (SPSS) v.17.0
software (SPSS Inc, Chicago, IL, USA) and Stata Statistic/
Data Analysis 9.1 (Stata Corporation, College Station,
TX, USA).
Additional file
Additional file 1: Table S1. Relative expression of miRNAs in T-ALL/
CD56+ pooled samples.
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